Compound class:
Synthetic organic
Comment: The structure for tibremciclib was obtained from proposed INN list 129 (August 2023) where it is described as a cyclin-dependent kinase inhibitor and antineoplastic agent. From patent analysis it appears to be a dual CDK4/6 inhibitor, a mechanism that is validated as a cancer therapy. CDK4/6 inhibition blocks the cell cycle at G1 phase and inhibits tumour cell proliferation.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Wang Y, Zhang C, Wang J, Ding L. (2021)
Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof. Patent number: US20210261546A1. Assignee: Betta Pharmaceuticals Co Ltd. Priority date: 21/06/2019. Publication date: 26/08/2021. |